Page 71 - Read Online

issues for these patients. Therefore in advanced patients Conflicts of interest
with orbital metastases, the alternative loco-regional There are no conflicts of interest.
treatments alone or in combination with systemic therapy
may constitute a viable treatment alternative to a surgical Patient consent
excision (exenteratio orbitis). [7] Obtained.

The currently proposed treatment of orbital metastases Ethics approval
in well-differentiated NETs includes surgery, beam The patient was treated within the standards of our institute
radiotherapy, especially for single and symptomatic and the report was approved.
lesions, peptide receptor radiotherapy or systemic medical
treatment. The integration of local treatment with SSA could REFERENCES
provide long-term disease control, preserving the patient’s
quality of life. Although the SSA objective response rates 1. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715
carcinoid tumors. Cancer 2003;97:934-59.
are limited (5-10%), these drugs are characterized by high 2. Pinchot SN, Holen K, Sippel RS, Shen H. Carcinoid tumors.
rates of disease stabilization, up to 50-60% in clinical Oncologist 2008;13:1255-69.
trials and with optimal profiles of safety and tolerability. 3. Zuetenhorst JM, Taal BG. Metastatic carcinoid tumors: a clinical
[8]
Moreover, the efficacy of SSA has been recently shown review. Oncologist 2005;10:123-31.
by two prospective, randomized, placebo-controlled trials, 4. Karcioglu ZA. Orbital tumours: Diagnosis and treatment. 2nd ed.
New York: Springer; 2005. p. 187-9.
the PROMID and CLARINET studies. [9,10] These studies 5. Peixoto RD, Lim HJ, Cheung WY. Neuroendocrine tumor metastatic
evaluated the impact of SSA treatment (octreotide long- to the orbit treated with radiotherapy. World J Gastrointest Oncol
acting release 30 mg every 28 days and Lanreotide ATG 2013;5:177-80.
120 mg every 28 days), leading to demonstration of their 6. Mehta JS, Abou-Rayyah Y, Rose GE. Orbital carcinoid metastases.
antiproliferative effects. The mean time to progression Ophthalmology 2006;113:466-72.
in the PROMID trial was 14.3 months in the octreotide 7. Borota OC, Kloster R, Lindal S. Carcinoid tumour metastatic to
the orbit with infiltration to the extraocular orbital muscle. APMIS
LAR arm compared to 6 months in the placebo arm. 2005;113:135-9.
[9]
In the CLARINET trial, Lanreotide ATG was associated 8. Modlin IM, Pavel M, Kidd M, Gustafsson BI. Review article:
with a significant improvement in mean progression free somatostatin analogues in the treatment of gastroenteropancreatic
survival compared to placebo (progression-free survival neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther
not reached in the treatment group vs. 18 months in the 2010;31:169-88.
placebo group). Based on these results, the use of SSA 9. Rinke A, Müller HH, Schade-brittinger C, Klose KJ, Barth P,
[10]
Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, Harder
is recommended for its antiproliferative effect in well J, Arnold C, Gress T, Arnold R; PROMID Study Group. Placebo-
differentiated NENs with an indolent course in patients controlled, double-blind, prospective, randomized study on the
with both functioning and non-functioning tumors. SSAs effect of octreotide LAR in the control of tumor growth in patients
represent a valid treatment option in cases where good with metastatic neuroendocrine midgut tumors. J Clin Oncol
quality of life is paramount and in which a surgical 2009;27:4656-63.
approach is not accepted, feasible or is contraindicated. 10. Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Seedláčková
E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Lanley A,
Financial support and sponsorship Martinez S, Blumberg J, Ruszniewski P. Lanreotide in Metastatic
Enteropancreatic Neuroendocrine Tumors. N Engl J Med
Nil. 2014;371:224-33.

344
Journal of Cancer Metastasis and Treatment ¦ Volume 2 ¦ August 31, 2016 ¦